pharmaphorum

OCTOBER 1, 2020

of the total capital invested in VC-backed startups in the US. By comparison, all-male founder teams got 89p and in total 83% of deals in the UK last year involved companies with no women at all on their founding teams. More is being done to widen the appeal of science, technology, engineering and maths (STEM) subjects, she adds. “We

Life Science 122

Life Science Engineer Production Research 122

ACRP blog

MARCH 21, 2024

The process of assessing clinical trial feasibility is in urgent need of improvement. Aimed at predicting whether a trial at a particular site will succeed, feasibility involves determining whether the site has the necessary patients, staff, technology, and other resources.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Research 59

XTalks

MAY 13, 2022

Curia is a global contract research, development and manufacturing organization (CDMO) that specializes in drug discovery, spanning the entire product lifecycle from target to lead candidate identification, development, manufacturing feasibility, through to commercialization and post-marketing. USP <1207.1>:

Packaging 98

Packaging Packaging Containment Production 98

XTalks

MAY 31, 2023

These positive trends are primarily driven by advancements in therapeutic areas and emerging technologies within the biotech sector. percent of the total outstanding shares of Kenvue’s common stock (or 89.6 The report highlights the sustained momentum of large-cap biotech companies and the improved performance of small-cap firms.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

pharmaphorum

MAY 30, 2022

Each with their individual and specialised offerings, the two companies are preparing to perform clinical trials using their fortes – essentially revising how clinical trials are conducted using technology. To begin, the companies will perform a 1,000-person randomised control trial that will consist of four arms and last 16 weeks in total.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Big Data 97

XTalks

NOVEMBER 9, 2021

Perhaps popularized by the COVID-19 vaccines, RNA-based technologies now have the potential to become the next best pesticide to combat crop pests, like insects and fungal pathogens. Despite its effectiveness, RNA production costs were high, totalling a minimum of $600 per gram. In 2017, Monsanto Co.

RNA 98

RNA Gene Scientist Protein 98

Pfizer

JANUARY 27, 2023

The recommendation to convert the cMA to full MA is based on the totality of available efficacy, safety, and quality data provided by Pfizer. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. PAXLOVID is not approved for any use, including for use for the treatment of COVID-19.

Marketing 75

Marketing Production Drugs Licensing 75

XTalks

DECEMBER 1, 2020

Grail says that based on modelling data from its study, the test could potentially decrease the number of late-stage cancer diagnoses by nearly half and, in turn, reduce the total number of cancer deaths by about 20 percent. Related: Grail Gains FDA Breakthrough Status for Multi-Cancer Blood Test. Circulating DNA.

DNA 64

DNA Genome Genomics Regulation 64

The Pharma Data

OCTOBER 29, 2020

3Q20 total revenues of $1,588.7 Total revenues in the third quarter were $1,588.7 The negative impact of foreign currency on total revenues year-over-year was 2 percent, or $25.5 Total revenues. R&D (% total revenues). . . SG&A (% total revenues). . . million , a 26% increase over 3Q19.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

XTalks

NOVEMBER 22, 2021

The approval for the device comes after Los Angeles-based AppliedVR announced it had secured $36 million in a series B funding round earlier this month, which brings the company’s total funding to $71 million. The funding round included investments from F-Prime Capital, JAZZ Venture Partners, Sway Ventures and SVB Ventures.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials Trials 52

The Pharma Data

JANUARY 30, 2021

“The latest data from the COMMENCE study are encouraging and speak to the promise of RESILIA tissue as a significant advancement in technology for patients with valve disease.” Data were collected for a total of five years and a subset of these patients will continue to be evaluated through 10 years.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Production 52

The Pharma Data

NOVEMBER 15, 2020

Diadem Also Provides Update on Intellectual Property Status of the AlzoSure Technology. Separately, the company provided an update on the status of the intellectual property protecting its AlzoSure ® technology. MILAN , Nov. MILAN , Nov. ” Diadem also provided an update on its intellectual property.

Development 40

Development In-Vitro Antibody Production 40